← Back to Screener
Bristol-Myers Squibb Co. (BMY)
Price$57.27
Value ScoreB
Growth ScoreC
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)8.48%
Price vs S&P 500 (4W)1.99%
VGM Score59.45
Market Capitalization$116.95B
P/E Ratio (Annual)16.58x
Indicated Dividend Yield (Annual)4.45%
All Metrics
P/CF (Annual)8.26x
Book Value / Share (Quarterly)$9.83
P/TBV (Annual)44.28x
Indicated Dividend (Annual)$2.52
Revenue Growth (3Y)1.45%
Cash Flow / Share (Quarterly)$5.83
Payout Ratio (TTM)125.78%
Price vs S&P 500 (YTD)-1.98%
Gross Margin (TTM)53.71%
Net Profit Margin (TTM)12.33%
EPS (TTM)$3.36
10-Day Avg Trading Volume13.17M
EPS Excl Extra (TTM)$3.36
Revenue Growth (5Y)2.54%
EPS (Annual)$3.46
Dividend / Share (Annual)$2.51
ROI (Annual)11.09%
Gross Margin (Annual)72.62%
Net Profit Margin (5Y Avg)8.55%
Cash / Share (Quarterly)$5.14
P/E Basic Excl Extra (TTM)19.57x
Revenue Growth QoQ (YoY)2.57%
P/E Normalized (Annual)16.58x
ROA (Last FY)7.83%
Revenue Growth TTM (YoY)1.78%
EBITD / Share (TTM)$6.76
ROE (5Y Avg)10.10%
Operating Margin (TTM)17.10%
Cash Flow / Share (Annual)$6.38
P/B Ratio5.83x
P/B Ratio (Quarterly)6.17x
Net Income / Employee (Annual)$217,000
EV / Revenue (TTM)3.13x
Net Interest Coverage (TTM)9.51x
ROA (TTM)8.68%
EPS Growth QoQ (YoY)8.67%
EV / EBITDA (TTM)14.60x
EPS Incl Extra (Annual)$3.46
Current Ratio (Annual)1.26x
Quick Ratio (Quarterly)1.28x
3-Month Avg Trading Volume12.20M
52-Week Price Return19.71%
EV / Free Cash Flow (Annual)11.82x
P/E Incl Extra (TTM)19.57x
Revenue / Employee (TTM)$1,491,800
Tangible BV / Share (Quarterly)$0.89
P/S Ratio (Annual)2.43x
Asset Turnover (Annual)0.54x
52-Week High$62.89
Operating Margin (5Y Avg)13.60%
EPS Excl Extra (Annual)$3.46
CapEx CAGR (5Y)11.73%
Tangible BV CAGR (5Y)-29.03%
26-Week Price Return16.40%
Quick Ratio (Annual)1.14x
13-Week Price Return-5.71%
Total Debt / Equity (Annual)2.44x
Current Ratio (Quarterly)1.42x
Enterprise Value$151.84B
Revenue / Share Growth (5Y)4.65%
Asset Turnover (TTM)0.70x
Book Value / Share Growth (5Y)-11.63%
Revenue / Employee (Annual)$1,482,900
Inventory Turnover (Annual)5.03x
Pretax Margin (Annual)19.36%
Cash / Share (Annual)$5.30
3-Month Return Std Dev26.51%
Gross Margin (5Y Avg)76.36%
Net Income / Employee (TTM)$183,900
EBITDA CAGR (5Y)36.81%
EBITDA Interim CAGR (5Y)-4.08%
ROE (Last FY)38.19%
Net Interest Coverage (Annual)10.58x
EPS Basic Excl Extra (Annual)$3.46
P/FCF (TTM)8.60x
Receivables Turnover (TTM)5.55x
EV / Free Cash Flow (TTM)12.75x
Total Debt / Equity (Quarterly)2.22x
EPS Incl Extra (TTM)$3.36
Receivables Turnover (Annual)5.02x
ROI (TTM)12.10%
Dividend Growth Rate (5Y)6.51%
P/S Ratio (TTM)2.41x
Pretax Margin (5Y Avg)10.99%
Revenue / Share (Annual)$23.64
Tangible BV / Share (Annual)$1.17
Forward P/E9.14x
Free OCF CAGR (5Y)-0.69%
Price vs S&P 500 (52W)-4.65%
P/E Ratio (TTM)19.57x
EPS Growth TTM (YoY)26.27%
Year-to-Date Return6.17%
5-Day Price Return4.22%
EPS Normalized (Annual)$3.46
ROA (5Y Avg)3.91%
Net Profit Margin (Annual)14.64%
Month-to-Date Return0.16%
Cash Flow / Share (TTM)$8.63
EBITD / Share (Annual)$6.71
EPS Growth (3Y)5.47%
Operating Margin (Annual)21.50%
LT Debt / Equity (Annual)2.32x
P/CF (TTM)8.79x
ROI (5Y Avg)5.36%
P/E Excl Extra (TTM)19.57x
LT Debt / Equity (Quarterly)2.10x
EPS Basic Excl Extra (TTM)$3.36
P/TBV (Quarterly)67.89x
Payout Ratio (Annual)71.52%
P/B Ratio (Annual)5.94x
Dividend / Share (TTM)$3.69
Inventory Turnover (TTM)3.78x
Pretax Margin (TTM)16.17%
Book Value / Share (Annual)$9.18
Price vs S&P 500 (13W)-13.97%
Dividend Yield (TTM)6.43%
Beta0.23x
P/FCF (Annual)9.10x
Revenue / Share (TTM)$23.68
ROE (TTM)41.64%
52-Week Low$42.52
vGradeB
gGradeC
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 261.58est. 1.43
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
3.53
3.53
3.53
3.50
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | B | $34.19 |
About
Bristol Myers Squibb is a biopharmaceutical company with leading capabilities in immuno-oncology and a broad portfolio spanning cardiovascular, oncology, and immunology therapies. The company is heavily concentrated in the US market, which accounts for approximately 70% of revenues—above the industry average.